Rapid biochemical response to denosumab in fibrous dysplasia of bone: Report of two cases

Osteoporosis International

Volumn 25, Issue 2, 2014, Pages 777-782

  Ganda, K ^a,b   Seibel, M J ^a,b  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bone turnover markers; Denosumab; Fibrous dysplasia; Response; Therapy

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; AMINO TERMINAL COLLAGEN TYPE I PROPEPTIDE; BIOCHEMICAL MARKER; CALCIUM; COLLAGEN; CREATININE; DENOSUMAB; DEOXYPYRIDINOLINE; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ADULT; ALBRIGHT SYNDROME; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TURNOVER; BUTTOCK; CAFE AU LAIT SPOT; CALCIUM BLOOD LEVEL; CASE REPORT; CHILDHOOD; CHOLELITHIASIS; COMPUTER ASSISTED TOMOGRAPHY; CRANIOFACIAL MALFORMATION; CREATININE BLOOD LEVEL; DRUG INFUSION; FEMALE; FEMUR; FEMUR OSTEOTOMY; FIBROUS DYSPLASIA; FIBULA; FOOT; GAIT DISORDER; HIP PAIN; HUMAN; HYPOCITRATURIA; INFORMED CONSENT; INTRAMEDULLARY NAILING; LEG MALFORMATION; MALE; MAXILLA; MEDICAL HISTORY; MIDDLE AGED; NEPHROLITHIASIS; PARATHYROID HORMONE BLOOD LEVEL; PELVIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUBERTY; RIB; SHOULDER; TIBIA; TREATMENT RESPONSE; URINARY EXCRETION; VARUS DEFORMITY; VISUAL ANALOG SCALE; VITAMIN BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; BONE REMODELING; DRUG EFFECTS; FIBROUS DYSPLASIA OF BONE; PATHOPHYSIOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; FEMALE; FIBROUS DYSPLASIA OF BONE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; RANK LIGAND; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84899122436     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2585-1     Document Type: Article

References (24)

1. Collins MTR, M. Bianco, P. (2008) Fibrous Dysplasia. In: Rosen C (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th edn. The American Society for Bone and Mineral Research, pp 423-427
2. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S (1996) Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright Syndrome. J Clin Investig 98(1):30-35 (Pubitemid 26243817)
3. Riminucci M, Kuznetsov SA, Cherman N, Corsi A, Bianco P, Robey PG (2003) Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone 33(3):434-442 (Pubitemid 37103260)
4. Weinstein LS, Shenker A, Gejman P, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright Syndrome. N Engl J Med 325:1688-1695
5. Albright F, Butler A, Hampton A, Smith P (1937) Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 216(17):727-746
6. Riminucci M, Collins MT, Fedarko N, Cherman N et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Investig 112(5):683-692 (Pubitemid 38057709)
7. Chapurlat RD, Delmas PD, Liens D, Meunier PJ (1997) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12(10):1746-1752 (Pubitemid 27422377)
8. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ (2004) Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 35(1):235-242 (Pubitemid 38789170)
9. Parisi MS, Oliveri B, Mautalen CA (2003) Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 33(4):582-588 (Pubitemid 37222384)
10. Weinstein RS (1997) Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Miner Res 12(8):1314-1315
11. Kitagawa Y, Tamai K, Ito H (2004) Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. J Orthop Sci 9(5):521- 525
12. Chapurlat RD (2006) Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 21(Suppl 2):P114-P119
13. Plotkin H (2003) Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 88(10):4569-4575
14. Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, Bassim C, Cherman N, Ellsworth M, Kasa-Vubu JZ, Farley FA, Molinolo AA, Bhattacharyya N, Collins MT (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27(7):1462-1470
15. Papapoulous SE (2008) Bisphosphonates for postmenopausal osteoporosis. In: Rosen C (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. The American Society for Bone and Mineral Research, pp 237-241
16. Weinstein RS, Roberson PK, Stavros CM (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53-62
17. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
18. Piersanti S, Remoli C, Saggio I, Funari A, Michienzi S, Sacchetti B, Robey PG, Riminucci M, Bianco P (2010) Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors. J Bone Miner Res 25(5):1103-1116
19. Mansoori LS, Catel CP, Rothman MS (2010) Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review. Endocr Pract 16(5):851-854
20. Dumitrescu CE, Collins MT (2008) McCune-Albright syndrome. Orphanet J Rare Dis 3:12
21. Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96(2):394-402
22. Grasemann C, Schundeln MM, Hovel M, Schweiger B, Bergmann C, Herrmann R, Wieczorek D, Zabel B, Wieland R, Hauffa BP (2013) Effects of RANK-ligand antibody (Denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease. J Clin Endocrinol Metab 98(8):3121-3126
23. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809-1822 (Pubitemid 46698462)
24. Talreja DB (2012) Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assess 1:30-33